CELLTIUM INC

Celltium Inc. is a biotechnology company focused on the discovery and development of transformative therapeutics for Charcot-Marie-Tooth disease type 1A (CMT1A) and related neurodegenerative disorders. Our proprietary high-throughput screening platform has enabled the identification of novel drug candidates targeting key molecular mechanisms involved in CMT1A, specifically the restoration of myelination. Celltium is progressing these candidates through preclinical evaluation, with a commitment to addressing the significant unmet medical need in CMT1A and similar neurological diseases.